switching to tirzepatide from semaglutide Mounjaro: Safe Guide Switching from Semaglutide to Tirzepetide

In the phase III PIONEER clinical trial program, oral semaglutide was shown to reduce glycated hemoglobin and body weight compared with placebo and active comparators in patients with T2D, with no new safety signals reported

Looking ahead to late 2026, a wave of anticipated new therapeutic indications across a diverse range of clinical areas includes: Potential role as preventive medicines As incretin-based therapies continue to demonstrate a wide range of health benefits, interest is growing in their potential role as preventive medicines

By helping to lower inflammation and pain, semaglutide might support improved mobility, allowing people to stay active for longer

In the 2026 updates, CMS refined A Codes to improve product-level clarity, reporting accuracy, and reimbursement alignment, particularly for intermittent urinary catheter supplies

The Precision Peptide Genetic Test ($99 add-on) analyzes your GLP1R, GIPR, FTO, and MC4R variants across 150+ genetic insights, helping your provider predict semaglutide response and tolerability